EUVIMEDEUVIMED entdecken
Crossref

Icariside II sensitizes osteosarcoma to doxorubicin through the lincROR/Wnt/β-catenin signaling regulatory axis

Shu-Ting Zhou, Zhi-Peng Li, Yong-Xin Mai, Yu-Yan Wang, Feng-Xiang Pang, Jin-Fang Zhang, Xian-Lin Wu

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04760-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Shu-Ting Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518000, People's Republic of China. Hauptthemen laut MEDLINE: Osteosarcoma, Doxorubicin, RNA, Long Noncoding, Wnt Signaling Pathway. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sanming Project of Medicine in Shenzen Municipality, Shenzhen Science and Technology Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) is a widely used chemotherapeutic drug for human osteosarcoma (OS). However, the acquired resistance of OS to DOX is a common phenomenon among OS patients, which seriously constrains its therapeutic efficacy in clinical practice. Improving the sensitivity of OS cells to DOX is therefore clinically significant for OS patients. Traditional Chinese medicine provides a potential strategy for reversing DOX resistance, among which Icariside II (ICS II), the flavonol glycoside derived from epimedium herb, has been reported to alleviate drug resistance in a variety of cancers, but the specific mechanism is still unclear. The emergence of long non-coding RNAs (lincRNAs) opens a new door for the mechanism underlying drug resistance. As an important carcinogenic lincRNA, lincROR was frequently dysregulated in various cancers and closely linked with multiple biological activities including proliferation, migration, invasion, and drug resistance. In the present study, a positive correlation between lincROR and DOX resistance was identified in OS cells. It was also found that lincROR overexpression promoted while its knockdown suppressed the DOX resistance in vitro and in vivo. The further investigation showed that the inactivation of Wnt/β-catenin induced by lincROR actively participated in this Icariside II-mediated DOX resistance. In summary, Icariside II sensitized the OS cells to DOX treatment and promoted the therapeutic effects mainly through the lincROR/Wnt/β-catenin regulatory axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaDoxorubicinRNA, Long NoncodingWnt Signaling PathwayFlavonoidsBone NeoplasmsAntibiotics, AntineoplasticHumansAnimalsCell Line, TumorDrug Resistance, NeoplasmMice, NudeMice, Inbred BALB CMiceXenograft Model Antitumor AssaysMale

Stichwörter der Autor:innen

Doxorubicin resistanceIcariside IILincRORWnt/β-catenin pathway

Substanzen

DoxorubicinRNA, Long Noncodingbaohuoside IFlavonoidsAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518000, People's Republic of China.
  • Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.
  • Department of Rehabilitation, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People's Republic of China.
  • Department of Traditional Chinese Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, People's Republic of China.
  • Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518000, People's Republic of China. zhangjf06@gzucm.edu.cn.
  • Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, 518000, People's Republic of China. wxlbad@163.com.

Förderung

  • National Natural Science Foundation of China
  • Sanming Project of Medicine in Shenzen Municipality
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Zhou, S. T., Li, Z. P., Mai, Y. X., Wang, Y. Y., Pang, F. X., Zhang, J. F., & Wu, X. L. (2025). Icariside II sensitizes osteosarcoma to doxorubicin through the lincROR/Wnt/β-catenin signaling regulatory axis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04760-1

Vancouver

Zhou ST, Li ZP, Mai YX, Wang YY, Pang FX, Zhang JF, et al. Icariside II sensitizes osteosarcoma to doxorubicin through the lincROR/Wnt/β-catenin signaling regulatory axis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04760-1

BibTeX
@article{Zhou2025,
  author = {Zhou, Shu-Ting and Li, Zhi-Peng and Mai, Yong-Xin and Wang, Yu-Yan and Pang, Feng-Xiang and Zhang, Jin-Fang and Wu, Xian-Lin},
  title = {Icariside II sensitizes osteosarcoma to doxorubicin through the lincROR/Wnt/β-catenin signaling regulatory axis},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04760-1}
}
Kostenlos starten →